Oxford BioTherapeutics Ltd. (OBT)

https://www.oxfordbiotherapeutics.com

Oxford BioTherapeutics is a clinical stage oncology company based in Oxford, UK and San Jose, USA; with a pipeline of first-in-class immuno-oncology (IO) and antibody-drug conjugate (ADC) based therapies designed to fulfill major unmet patient needs in cancer therapeutics. These include bispecific, Chimeric Antigen Receptor T Cell (CAR-T), ADC and Antibody Dependent Cell-mediated Cytotoxicity (ADCC) therapeutics. OBT's first clinical program, OBT076, initiated expansion in a U.S. Clinical Trial in 2021 in patients with advanced or refractory solid tumors, including gastric, bladder, ovarian and lung cancer, where CD205 is overexpressed. Infiltration of tumors by immunosuppressive cells correlates with adverse outcomes (lower profession free and overall survival), suggesting that this process contributes to the progression of several cancers. OBT’s proprietary OGAP® target discovery platform is based on one of the world’s largest proprietary cancer membrane proteomic databases, with data on over 5,000 cancer cell proteins providing unique, highly qualified oncology targets, of which three programs are in clinical development in the USA and Europe. OBT's IO discovery process provides unique insights into the cancer - immune cell synapse and has identified several novel IO monoclonal and bispecific antibody candidates for cancer therapies. OBT’s pipeline and development capabilities have been validated through multiple strategic partnerships including with Boehringer Ingelheim and our cell therapy research collaboration with Kite Pharma as well as other world leaders in antibody development (such as Amgen, Immunogen, WuXi, Medarex (BMS), Alere (Abbott), BioWa, and Nerviano). OBT has a strong oncology focused management team and board with significant experience in developing IO and antibody-based therapies. *

	Start	2008-12-01 renamed
	Predecessor	Oxford Genome Sciences (UK) Ltd. (OGeS)
	Industry	antibody-drug conjugate (ADC)
	Industry 2	Oxford Genome Anatomy Project (OGAP) database
	Person	Rohlff, Christian (Oxford BioTherapeutics 201506 CEO before Oxford Genome Sciences CEO)
	Person 2	Wilson, Keith (Oxford BioTherapeutics 201506 CSO)

	Region	Abingdon, Oxfordshire
	Country	United Kingdom (GB)
	Street	94a Milton Park
	City	OX14 4RY Abingdon, Oxfordshire
	Tel	+44-1235-861770
		Address record changed: 2022-04-14

Basic data	Employees	n. a.

		* Document for ï¿½About Sectionï¿½: Oxford BioTherapeutics Ltd.. (4/13/22). "Press Release: Oxford BioTherapeutics Grants Third Exclusive License to Boehringer Ingelheim for Development and Commercialization of Antibody Products to a Novel Oncology Target". Oxford & San Jose, CA.

		Record changed: 2022-04-14